Reassessing high-dose ranibizumab in the era of durable anti-VEGF therapy.

Front Ophthalmol (Lausanne) · 2026 · PMC13078969 · PMID 41994559

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

The retrospective analysis reveals a significant reduction in treatment burden that was previously described only as a numerical trend.

also in 708 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.